Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.52 |
| ▸ | GNRHR | P30968 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389190 | 0.90 | RXRA (0.53) | RXRANR1H2NR1H3 | |
| SCHEMBL2389061 | 0.87 | RXRA (0.54) | RXRANR1H2NR1H3 | |
| SCHEMBL2386307 | 0.85 | RXRA (0.59) | RXRANR1H2NR1H3 | |
| SCHEMBL2387739 | 0.84 | RXRA (0.51) | RXRANR1H2NR1H3 | |
| SCHEMBL2389548 | 0.84 | RXRA (0.56) | RXRANR1H2NR1H3 | |
| SCHEMBL2387164 | 0.83 | RXRA (0.51) | RXRANR1H2NR1H3GNRHR | |
| SCHEMBL2389388 | 0.82 | RXRA (0.63) | RXRANR1H2NR1H3 | |
| SCHEMBL2389321 | 0.82 | RXRA (0.51) | RXRANR1H2NR1H3 | |
| SCHEMBL2388571 | 0.81 | RXRA (0.53) | RXRANR1H2NR1H3 | |
| SCHEMBL2389137 | 0.81 | RXRA (0.47) | RXRANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.